The trial also concluded that the EGFR inhibitor cetuximab provided no added survival benefit. "This sets a new benchmark of survival for patients with inoperable stage III NSCLC treated with chemoradiation," said principal investigator Jeffrey D. Bradley, MD, Professor of Radiation Oncology an...
PD1)/程序性细胞死亡配体1(programmed cell death ligand 1,PD-L1)单克隆抗体在新辅助免疫治疗联合化疗方案中显著地提高了早期可手术的NSCLC患者的主要病理缓解(major pathological response,MPR)率和无事件生存(even-free survival,EFS)率...
2024年欧洲肺癌大会(ELCC)正于中欧时间3月20日-23日在捷克布拉格火热召开中。一项评估接受放化疗(CRT)治疗的III期不可切表皮生长因子受体(EGFR)突变非小细胞肺癌(NSCLC)治疗模式和临床结果的真实世界(RW)研究(LEROS研究)成功入选本次E...
PD1)/程序性细胞死亡配体1(programmed cell death ligand 1,PD-L1)单克隆抗体在新辅助免疫治疗联合化疗方案中显著地提高了早期可手术的NSCLC患者的主要病理缓解(major pathological response,MPR)率和无事件生存(even-free survival,EFS)率,已成为早期可手术的NSCLC患者的标准治疗方案之一。
Long-term survival outcome of radiation therapy for unresectable, locally advanced non-small cell lung cancer: Single center experience at Hospital 175. While surgery remains the cornerstone of treatment for early-stage NSCLC, patients with locally advanced or inoperable NSCLC require alternative therapeut...
Circulating tumour DNA (ctDNA) refers to the fraction of cell-free DNA in a patient’s blood that originates from a tumour. Advances in DNA sequencing technologies and our understanding of the molecular biology of tumours have resulted in increased inter
and resistance that is most frequently associated with tumor recurrence. Perioperative platinum-based chemotherapy is associated with a survival rate that is only 5.4% higher than that with surgery alone [3]. Even after curative resection, ~60% of patients with stage IIIA disease still develop recu...
[1]:一项Ⅲ期随机对照临床研究, 共纳入878例复发性或晚期非鳞NSCLC患者,数据显示, 卡铂+紫杉醇联合贝伐珠单抗一线治疗比较单纯化疗方案可明显延长患者生存时间 (中位OS 12.3个月 vs 10.3个月,HR=0.79,P=0.003;中位PFS 6.2个月 vs 4.5个月,HR=0.66,P<0.001),提高客观缓解率(objective response rate,ORR)(35...
What was remarkable about this study is that the disease-free survival [DFS] outcomes were quite impressive with osimertinib, with hazard ratios [HRs] of 0.17 and 0.12 [in those with] stage II and IIIA disease, respectively. [We] really saw a profound DFS advantage in the os...
[7] Roy S. Herbst et al., Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).. JCO 41, LBA3-LBA...